https://pharma-industry-review.com/lillys-jaypirca-outperforms-imbruvica-in-cll-head-to-head-phase-3-trial
Lilly's Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Jul 29, 2025 - BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients.
lilly sjaypircacllheadphase